Chlamydia pneumoniae

GeneProof Announces Expansion of its IVDR-Certified PCR Portfolio

Retrieved on: 
Tuesday, October 3, 2023
Ureaplasma urealyticum, CT, IVDR, Urinary tract infection, Workflow, CP, Infection, Neisseria gonorrhoeae, Chlamydia trachomatis, Real-time, Quality management system, Mycoplasma genitalium, Mycoplasma hominis, NG, Canine vector-borne disease, Diagnosis, PCR, Chlamydia pneumoniae, Medical device, Telecommunications, Ureaplasma, EU, Mycoplasma, Chlamydia

BRNO, Czech Republic, Oct. 3, 2023 /PRNewswire/ -- GeneProof, a leader in molecular diagnostics, today announced the addition of six new IVDR-certified PCR kits to its expansive portfolio.

Key Points: 
  • BRNO, Czech Republic, Oct. 3, 2023 /PRNewswire/ -- GeneProof, a leader in molecular diagnostics, today announced the addition of six new IVDR-certified PCR kits to its expansive portfolio.
  • This comes as a testament to the company's dedication to delivering its entire portfolio of approximately 80 products as IVDR compliant by 2027.
  • Currently, 27 products are IVDR cleared, with 16 that are Notified Body certified in class C and B.
  • GeneProof was among the first to obtain the EU Certificate for Quality Management System under the new Regulation (EU) 2017/746 IVDR.

QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels

Retrieved on: 
Monday, May 16, 2022
Security, Data Management, Technology, Pharmaceutical, General Health, Infectious Diseases, Hospitals, Genetics, Clinical Trials, Biotechnology, Science, Software, Networks, Internet, Research, Health, Senior, QIAGEN, Risk, DNA, Blood, QGEN, U.S. Securities and Exchange Commission, Urinary tract infection, Bacteria, Solution, Knowledge, HUS, Molecular diagnostics, Research, Life, RNA, Budget, STEC, Automation, Protein, SEC, Hemolytic–uremic syndrome, Growth, Laboratory, NYSE, Chlamydia pneumoniae, Vaccine, Academy, Insight, Pharma

The launch of QIAstat-Dx Rise comes after the award of European CE-marking that significantly expands QIAGENs offering in syndromic testing, which is becoming an increasingly important tool in laboratories settings to test simultaneously for multiple pathogens from one sample.

Key Points: 
  • The launch of QIAstat-Dx Rise comes after the award of European CE-marking that significantly expands QIAGENs offering in syndromic testing, which is becoming an increasingly important tool in laboratories settings to test simultaneously for multiple pathogens from one sample.
  • The launch of QIAstat-Dx Rise syndromic testing platform provides automated, comprehensive pathogen testing for higher-demand medical institutions, said Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area at QIAGEN.
  • QIAstat-Dx Rise and its test cartridges are a closed system for hands-off sample preparation and processing.
  • Building on the existing QIAstat-Dx Analyzer with up to four analytical modules, QIAstat-Dx Rise is a flexible new option for increased testing capacity.

Nabriva Announces Availability of XENLETA® (lefamulin) in a 10-Count Oral Pack

Retrieved on: 
Thursday, November 11, 2021
CYP3A4, Therapy, Moxifloxacin, CDAD, Food, COVID-19, Legionella pneumophila, Infection, Staphylococcus aureus, Review, Insomnia, Risk, Cutis laxa, Hypersensitivity, Fosfomycin, Pregnancy, Chlamydia pneumoniae, Clostridioides, Food and Drug Administration, Haemophilus influenzae, Streptococcus pneumoniae, Complicated, Research, Woman, Vomiting, Headache, Pyelonephritis, GLOBE, Tablet, Marketing, Patient, FDA, Private Securities Litigation Reform Act, NASDAQ, Fetus, CYP3A, Human, Mycoplasma pneumoniae, Liver, U.S. Securities and Exchange Commission, Arrhythmia, Nausea, Pharmacy, QT, Urinary tract infection, ABSSSI, Merck, European Union, Linezolid, Diarrhea, IV, Birth, Bacteria, Bronchopneumonia, Physician, Hypokalemia, Pharmaceutical industry, Vaccine, Birth control

XENLETA has in vitro activity and demonstrated clinical efficacy against the most common pathogens that cause community-acquired bacterial pneumonia (CABP).

Key Points: 
  • XENLETA has in vitro activity and demonstrated clinical efficacy against the most common pathogens that cause community-acquired bacterial pneumonia (CABP).
  • Our community-based sales force is excited to communicate the availability of the 10-count oral pack or X pack to their target customers.
  • XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team.
  • Efficacy of XENLETA was demonstrated in two multicenter, multinational, double-blind, double-dummy, non-inferiority trials assessing a total of 1,289 patients with CABP.